Mineralys Therapeutics Statistics
Total Valuation
MLYS has a market cap or net worth of $2.13 billion. The enterprise value is $1.48 billion.
Important Dates
The next estimated earnings date is Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MLYS has 82.45 million shares outstanding. The number of shares has increased by 39.38% in one year.
| Current Share Class | 82.45M |
| Shares Outstanding | 82.45M |
| Shares Change (YoY) | +39.38% |
| Shares Change (QoQ) | +14.10% |
| Owned by Insiders (%) | 0.81% |
| Owned by Institutions (%) | 86.15% |
| Float | 60.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.27 |
| P/TBV Ratio | 3.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 43.76
| Current Ratio | 43.76 |
| Quick Ratio | 43.45 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -36.91% and return on invested capital (ROIC) is -25.45%.
| Return on Equity (ROE) | -36.91% |
| Return on Assets (ROA) | -24.58% |
| Return on Invested Capital (ROIC) | -25.45% |
| Return on Capital Employed (ROCE) | -26.38% |
| Weighted Average Cost of Capital (WACC) | 8.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.03M |
| Employee Count | 76 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +94.08% in the last 52 weeks. The beta is 0.69, so MLYS's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | +94.08% |
| 50-Day Moving Average | 27.20 |
| 200-Day Moving Average | 30.80 |
| Relative Strength Index (RSI) | 41.08 |
| Average Volume (20 Days) | 1,214,540 |
Short Selling Information
The latest short interest is 8.78 million, so 10.65% of the outstanding shares have been sold short.
| Short Interest | 8.78M |
| Short Previous Month | 8.37M |
| Short % of Shares Out | 10.65% |
| Short % of Float | 14.55% |
| Short Ratio (days to cover) | 6.15 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -170.60M |
| Pretax Income | -154.65M |
| Net Income | -154.65M |
| EBITDA | -170.55M |
| EBIT | -170.60M |
| Earnings Per Share (EPS) | -$2.29 |
Full Income StatementBalance Sheet
The company has $656.64 million in cash and n/a in debt, giving a net cash position of $656.64 million or $7.96 per share.
| Cash & Cash Equivalents | 656.64M |
| Total Debt | n/a |
| Net Cash | 656.64M |
| Net Cash Per Share | $7.96 |
| Equity (Book Value) | 646.69M |
| Book Value Per Share | 7.93 |
| Working Capital | 646.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$142.42 million and capital expenditures -$15,000, giving a free cash flow of -$142.43 million.
| Operating Cash Flow | -142.42M |
| Capital Expenditures | -15,000 |
| Depreciation & Amortization | 59,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -142.43M |
| FCF Per Share | -$1.73 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |